Comparative Effects of Intravenously Administered Alizapride and Prochlorperazine in Cisplatin-Induced Emesis
| Autor: | G. Hyman, H. Roche, Gabriel G. Nahas, M. Stoopler, R. Desjardins, R. Ellison |
|---|---|
| Rok vydání: | 1987 |
| Předmět: |
Adult
Male Cancer Research Pyrrolidines Vomiting medicine.drug_class Pharmacology Prochlorperazine chemistry.chemical_compound Pharmacokinetics medicine Humans Antiemetic Distribution (pharmacology) Benzamide Aged Cisplatin business.industry General Medicine Middle Aged Crossover study Oncology chemistry Anesthesia Injections Intravenous Female Alizapride business medicine.drug |
| Zdroj: | Cancer Investigation. 5:89-93 |
| ISSN: | 1532-4192 0735-7907 |
| Popis: | A randomized, double blind crossover trial compared the antiemetic effects of alizapride, a benzamide, and prochlorperazine, a phenothiazine, both administered intravenously to 32 patients treated with chemotherapy combinations containing cisplatin. The total dose of alizapride administered to each patient was 14 mg/kg, and of prochlorperazine .56 mg/kg, divided in five doses. Although alizapride resulted in complete protection against emesis in 31% of the patients during their first course of cisplatin therapy, 42% of those who received alizapride had five or more episodes of emesis. Although prochlorperazine was less effective in offering complete protection against emesis, only 15% of the patients receiving this drug vomited more than five times. The duration of emesis during prochlorperazine treatment was also significantly shorter than during alizapride therapy (p less than 0.02). Optimal dosage and pharmacokinetic distribution of both drugs should be investigated further. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|